argenx SE (ARGX)
After hours:
| Previous Close | 382.50 |
| Open | 387.24 |
| Bid | 387.48 x 100 |
| Ask | 389.03 x 100 |
| Day's Range | 384.65 - 389.08 |
| 52 Week Range | 327.73 - 550.76 |
| Volume | |
| Avg. Volume | 264,360 |
| Market Cap | 23.079B |
| Beta (5Y Monthly) | 0.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.66 |
| Earnings Date | Jul 25, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 477.43 |
GlobeNewswireargenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:40 PM ET in Miami, FL. A live webcast of the fireside chat may be accessed on the Investors section of the argenx website at argenx.com/inv
Investor's Business DailyAfter Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."
Investor's Business DailyBiohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Biohaven stock tumbled Wednesday after the company's experimental protein-degrading drug lagged investor expectations.
